← Leaderboards
Leo I. Gordon
Northwestern University
$81,896
Attributed
$81,896
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$81,896 · 4
By mechanism
M01$81,896 · 4
Top collaborators
No co-investigators on record.
Most similar at Northwestern University
Same institution · by research overlap
- Theodore S Jardetzky$26,743,105
- Andrew M Evens$3,800,221
- Andrew Christian Larson$10,031,015
- William M. Miller$4,333,356
- Marcelo G. Bonini$11,843,749
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectMonoclonal AntibodyClinical ResearchCombination Cancer TherapyAntineoplasticsHuman Therapy EvaluationYttriumB Cell LymphomaNonhodgkin'S LymphomaB LymphocyteNeoplasm /Cancer RadioimmunotherapyNeoplasm /Cancer ImmunotherapyDrug Screening /EvaluationHybrid AntibodyImmunoglobulin GPlateletsRadiation Therapy DosageRadionuclidesRadiotracerNeoplasm /Cancer Radionuclide TherapyNeoplasm /Cancer Relapse /RecurrenceNeoplasm /Cancer Radiation TherapyCd AntigensImmunotherapy
Grant awards (7)
IDEC Y2B8 RADIOIMMUNOTHERAPY IN B CELL NON HODGKINS LYMPHOMA$0
M01 · FY2001 · RR
IDEC Y2B8 RADIOIMMUNOTHERAPY FOR NON HODGKINS LYMPHOMA AFTER RITUXIMAB$0
M01 · FY2001 · RR
IDEC Y2B8 RADIOIMMUNOTHERAPY COMPARED TO RITUXAN IN RELAPSED B CELL LYMPHOMA$0
M01 · FY2001 · RR
IDEC 10603--IDEC Y2B8 ADMINISTERED TO PATIENTS WITH B CELL LYMPHOMA$20,474
M01 · FY2000 · RR
IDEC Y2B8 RADIOIMMUNOTHERAPY COMPARED TO RITUXAN IN RELAPSED B CELL LYMPHOMA$20,474
M01 · FY2000 · RR
IDEC Y2B8 RADIOIMMUNOTHERAPY IN B CELL NON HODGKINS LYMPHOMA$20,474
M01 · FY2000 · RR
IDEC Y2B8 RADIOIMMUNOTHERAPY FOR NON HODGKINS LYMPHOMA AFTER RITUXIMAB$20,474
M01 · FY2000 · RR